Everand Logo

Welcome to Everand!

  • STAT

    Experts search for answers in limited information about mystery pneumonia outbreak in China

    The growing cluster of unexplained pneumonia cases in Wuhan has infectious disease experts parsing limited statements from Chinese authorities for clues to what is happening.
    by Helen Branswell Jan 04, 2020 5 minutes
    An aerial view of Wuhan, China

    The mysterious and growing cluster of unexplained pneumonia cases in the Chinese city of Wuhan has infectious disease experts parsing limited public statements from Chinese authorities for clues to what is happening.

    With machine-translated reports that the outbreak might be caused by a new virus, and perhaps even a new coronavirus — the family of viruses that produced both SARS and MERS — watchers are hoping that Chinese authorities will provide additional information soon.

    “I think we need to give them a couple of days but I want to hear something from a credible source on the investigations that are ongoing,” said Marion Koopmans, director of the department of virology at Erasmus Medical Center in Rotterdam, the Netherlands.

    As of Friday, health authorities in Wuhan reported , a big jump from the 27 reported on Tuesday. Eleven of the 44 were seriously ill, the Wuhan Municipal Health Commission said, though

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Brain Biopsies On ‘Vulnerable’ Patients At Mount Sinai Set Off Alarm Bells At FDA, Documents Show
    A STAT Investigation: Brain biopsies on "vulnerable" patients at Mount Sinai set off alarm bells at FDA, documents show.
    STAT1 min read
    USDA Faulted For Disclosing Scant Information About Outbreaks Of H5N1 Avian Flu In Cattle
    With 28 herds in eight states infected with H5N1 bird flu, scientists are calling on the U.S. to release more data to help them assess the risk.
    STAT1 min read
    Opinion: STAT+: How AI Can Help Satisfy FDA’s Drug, Device Diversity Requirements
    To meet the Food and Drug Omnibus Reform Act, companies must rethink their current clinical trial strategies. Including AI and machine learning approaches can help.

    Related Books & Audiobooks